comparemela.com

Latest Breaking News On - Otsuka pharmaceutical europe - Page 2 : comparemela.com

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesUnited kingdomPeter greenleafSue evansDana lynchEuropean unionOtsuka pharmaceutical development commercialization incOtsuka pharmaceutical co ltdCommittee for medicinal products human useAurinia pharmaceuticals incEuropean congressDrug administrationEuropean commissionEuropean alliance of associationsOtsuka pharmaceutical europe ltdCorporate communications

Aurinia Pharmaceuticals Inc : Aurinia Announces Positive CHMP Opinion for LUPKYNIS (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study, demonstrating voclosporin to be safe and well

United statesUnited kingdomPeter greenleafSue evansDana lynchAurinia pharmaceuticals incEuropean commissionDrug administrationCorporate communicationsOtsuka pharmaceutical europe ltdEuropean unionEuropean medicines agencyOtsuka pharmaceutical development commercialization incAurinia pharmaceuticalsOtsuka pharmaceutical co ltdCommittee for medicinal products human use

Positive news for Aurinia s voclosporin drug Lupkynis for lupus nephritis

British Columbia-based Aurinia Pharmaceuticals Inc. announced that its voclosporin drug has been recommended for marketing authorization.

United kingdomRobert mcquadePeter greenleafSue evansBritish aurinia pharmaceuticals incEuropean commissionDrug administrationEuropean unionOtsuka pharmaceutical europe ltdEuropean medicines agencyOtsuka pharmaceutical co ltdCommittee for medicinal products human useBritish columbia based aurinia pharmaceuticalsMedicinal productsHuman useOtsuka pharmaceutical europe

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Pati

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with AripiprazoleOtsuka Pharmaceutical Europe Ltd. (“Otsuka”) and H. Lundbeck A/S (“Lundbeck”) today announce that the European.

United statesOtsuka europeThomas mikkel mortensenAlison rossAbilify maintenaOtsuka united kingdom pharma europe ltdOtsuka pharmaceutical company ltdWorld health organisationOtsuka pharmaceutical europe ltdEuropean medicines agencyEuropean medicines agency commencesMedia relations lead corpOtsuka holdings co ltdEuropean medicines agency commences reviewMonth long acting injectableMaintenance treatment

Aurinia: Redemption On Lupkynis Sale And Possible EMA Approval (NASDAQ:AUPH)

Aurinia & its partner OPEL expect a decision from the EMA in the 2H22 on whether or not Lupkynis will be approved for the Europe. Read more on AUPH stock here.

United statesLupkynis voclosporinEuropean congressAurinia pharmaceuticals incLupkynis to otsuka pharmaceutical europe ltdEuropean alliance of associationsEuropean unionEuropean medicines agencyAurinia pharmaceuticalsEuropean renal associationLiquid bubbleNorth americaOtsuka pharmaceutical europeMarketing authorization applicationEuropean alliance

vimarsana © 2020. All Rights Reserved.